$TPIV $3.16 new HODs starting slow ascent with new CEO Peter Hoang. $TPIV new TNBC Clinical Trial underway with first recruit. Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer https://clinicaltrials.gov/ct2/show/NCT03012100?term=NCT03012100&rank=1 NCT03012100